Plain-English translation of NCT07581821 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications—sintilimab (an immunotherapy), anlotinib (a targeted therapy), and taxane-based chemotherapy—can help people whose nasopharyngeal cancer has come back or spread to other parts of the body. You would receive the medication if you've already tried other standard treatments. The goal is to see if combining these three drugs works better and is safe enough for patients like you.
Nasopharyngeal cancer that returns or spreads is very hard to treat, and many patients don't respond well to first-line treatments. This trial exists to find out whether combining these three different types of medication—each working in a different way to fight cancer—can offer hope to patients whose cancer has progressed despite previous therapy.
You likely qualify if…
You likely don't qualify if…
You would receive the three medications as an intravenous infusion and oral pills, with treatment cycles happening every 3 weeks. For the first 6 cycles (about 18 weeks), you'd receive all three drugs together; after that, you'd continue with the two other medications for up to 2 years total. You would have regular hospital visits for treatment, blood tests, and imaging scans to check how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China